Quick Answer
Travere Therapeutics, Inc. reported Revenue (ASC 606) of $490.73 million for fiscal year 2025.
Travere Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $490.73M | +110.5% |
| 2024 | $233.18M | +60.5% |
| 2023 | $145.24M | +32.7% |
| 2022 | $109.46M | -17.0% |
| 2021 | $131.84M | -33.5% |
| 2020 | $198.32M | +13.1% |
| 2019 | $175.34M | +6.8% |
| 2018 | $164.25M | +6.0% |
| 2017 | $154.94M | +16.0% |
| 2016 | $133.59M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $164.86M | +162.1% | +44.0% |
| June 30, 2025 | $114.45M | +111.5% | +40.0% |
| March 31, 2025 | $81.73M | +97.5% | +29.9% |
| September 30, 2024 | $62.90M | +69.6% | +16.2% |
| June 30, 2024 | $54.12M | +68.1% | +30.8% |
| March 31, 2024 | $41.37M | +33.9% | +11.5% |
| September 30, 2023 | $37.09M | +32.1% | +15.2% |
| June 30, 2023 | $32.20M | -40.6% | +4.2% |
- Travere Therapeutics, Inc. showed an increase of +110.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Travere Therapeutics, Inc.’s revenue (asc 606) has grown by 267.3% (from $133.59 million to $490.73 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: